SCHEMBL5216754

SCHEMBL5216754

COC(=O)Nc1ccc(N2CCOCC2)c(F)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.63
NPC1 O15118 6/20 0.61
RAB9A P51151 5/20 0.61
KMT2A Q03164 1/20 0.61
L3MBTL1 Q9Y468 3/20 0.60
LDHA P00338 1/20 0.57
LDHB P07195 1/20 0.57
MTOR P42345 2/20 0.56
MAPT P10636 2/20 0.56
LMNA P02545 3/20 0.55
DGAT1 O75907 1/20 0.54
SMN1; SMN2 Q16637 4/20 0.53
ALDH1A1 P00352 3/20 0.53
HPGD P15428 3/20 0.53
TSHR P16473 2/20 0.53
GAA P10253 1/20 0.53
KDM4E B2RXH2 1/20 0.52
TP53 P04637 1/20 0.51
ALOX15 P16050 1/20 0.51
MAPK1 P28482 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2406029 0.88 HTT (0.58) HTTNPC1RAB9AKMT2AL3MBTL1
SCHEMBL20922083 0.86 HTT (0.66) HTTNPC1RAB9AKMT2AL3MBTL1
SCHEMBL16204421 0.86 HTT (0.60) HTTNPC1RAB9AKMT2AL3MBTL1
SCHEMBL483939 0.85 LDHA (0.56) HTTNPC1RAB9AKMT2AL3MBTL1
SCHEMBL6988691 0.85 HTT (0.67) HTTNPC1RAB9AKMT2AL3MBTL1
SCHEMBL13263349 0.84 NPC1 (0.62) HTTNPC1RAB9AKMT2AL3MBTL1
SCHEMBL21479386 0.83 KDM4E (0.75) HTTNPC1RAB9AKMT2AL3MBTL1
SCHEMBL15546417 0.82 NPC1 (0.69) HTTNPC1RAB9AKMT2AL3MBTL1
SCHEMBL30771563 0.81 NPC1 (0.61) HTTNPC1RAB9AKMT2AL3MBTL1
SCHEMBL2152084 0.81 NPC1 (0.61) HTTNPC1RAB9AKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115902018-A Detection method of linezolid isomer 江苏晨牌药业集团股份有限公司 2023-04-04 CN disclosed
US-RE47606-E1 Process for the preparation of linezolid OPTIMUS DRUGS PRIVATE LIMITED (IN) 2019-09-17 US disclosed
WO-2017182853-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF LINEZOLID OPTIMUS DRUGS PVT LTD (IN) 2017-10-26 WO disclosed
US-9643939-B1 Process for the preparation of linezolid OPTIMUS DRUGS PRIVATE LIMITED (US) 2017-05-09 US disclosed
US-9643939-B1 Process for the preparation of linezolid OPTIMUS DRUGS PRIVATE LIMITED (US) 2017-05-09 US disclosed
US-9586913-B2 Processes for the preparation of linezolid using novel intermediates SYMED LABS LIMITED (IN) 2017-03-07 US disclosed
US-20160102064-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES SYMED LABS LIMITED (IN) 2016-04-14 US disclosed
WO-2014174522-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES SYMED LABS LIMITED (IN) 2014-10-30 WO disclosed
EP-1028940-B1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN CO LLC (US) 2007-04-18 EP disclosed
EP-1772453-A1 Process to produce Oxazolidinones Pharmacia & Upjohn Company LLC (US) 2007-04-11 EP disclosed
US-6492555-B2 REACTION OF A CARBAMATE WITH EITHER A (S)-SECONDARY ALCOHOL OR (S)-EPOXIDE OR (S)-ESTER; BACTERICIDES PHARMACIA & UPJOHN COMPANY 2002-12-10 US disclosed
US-20020095054-A1 Process to produce oxazolidinones PHARMACIA & UPJOHN COMPANY 2002-07-18 US disclosed
US-20020086900-A1 Methods of producing oxazolidinone compounds PERRAULT WILLIAM R (US) 2002-07-04 US disclosed
US-6410788-B1 BACTERICIDES; REACTING IMINE, CARBAMATE, ESTER, AMIDE AND EPOXIDE DERIVATIVES PHARMACIA & UPJOHN COMPANY 2002-06-25 US disclosed
WO-2002032857-A1 METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2002-04-25 WO disclosed
US-6362334-B1 OXAZOLIDINONE PHTHALAMIDE PHARMACIA & UPJOHN COMPANY 2002-03-26 US disclosed
US-20020032348-A1 Process to produce oxazolidinones PEARLMAN BRUCE ALLEN (US) 2002-03-14 US disclosed
EP-1028940-A1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY (US) 2000-08-23 EP disclosed
US-6107519-A Process to produce oxazolidinones PHARMACIA & UPJOHN COMPANY (US) 2000-08-22 US disclosed
WO-1999024393-A1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102064-A1 IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES CYP3A5, SBDS, MLYCD HTT 3785/4885NPC1 3226/4885RAB9A 2934/4885
US-20020095054-A1 Process to produce oxazolidinones ADH1A, ADH5, ADH1C HTT 3874/4885NPC1 3095/4885RAB9A 3277/4885
US-20020086900-A1 Methods of producing oxazolidinone compounds TET3, TET1, AZI2 HTT 559/4885NPC1 3328/4885RAB9A 4755/4885
US-20020032348-A1 Process to produce oxazolidinones ADH1A, ADH5, ADH1C HTT 3874/4885NPC1 3095/4885RAB9A 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.